Stay updated on Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.0%
    Check dated 2025-04-25T21:10:23.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The page has been updated to include new drug information related to gastric cancer treatments, specifically listing Capecitabine, 5-fluorouracil, Docetaxel, Oxaliplatin, and Leucovorin, while removing extensive details about a previous study involving pembrolizumab.
    Difference
    13%
    Check dated 2025-04-18T14:35:09.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The date has been updated from March 25, 2025, to February 20, 2025.
    Difference
    0.2%
    Check dated 2025-04-11T10:49:44.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.0%
    Check dated 2025-04-03T21:47:31.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version (v2.14.3) and a new last update date of March 25, 2025, replacing the previous estimated dates and version.
    Difference
    0.2%
    Check dated 2025-03-27T14:45:19.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the introduction of new treatment arms involving Pembrolizumab combined with specific chemotherapy regimens, and the removal of previous treatment arm references. Additionally, new metrics for evaluating treatment outcomes, such as Event-free Survival and Overall Survival, have been added.
    Difference
    6%
    Check dated 2025-02-26T19:57:39.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial page.